Abstract
BackgroundThe use of biological DMARDs to treat RA patients has increased over the past 15 years probably due to their efficacy and tolerability profile.ObjectivesDescribe persistence (time between biological agent initiation...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
